US FDA finalises guides to improve reporting of safety information in drug trials
This article was originally published in SRA
The US Food and Drug Administration has finalised two guidelines to help drug companies comply with its revised safety reporting requirements for investigational new drugs and bioavailability/bioequivalence studies that came into force in 20111-3.
You may also be interested in...
While good clinical practice inspectors in the UK and the US collaborate on matters of common interest, they say that mutual recognition is simply not possible.
Whoever takes over as chair of the Medicines and Healthcare products Regulatory Agency will play a key role in its plans to deliver a program of “ambitious business change.”
The International Council for Harmonisation has replaced its 1993 guideline on reproductive toxicity studies with an updated version.